Allergan Loses Appeal Over Validity of Restasis Patents

Bookmark
(Bloomberg) -- Allergan Plc’s patents on its blockbuster eye drug Restasis are invalid, a U.S. appeals court ruled Tuesday.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.